Natera, Inc. (NTRA) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Natera, Inc. is a diagnostics company utilizing cell-free DNA (cfDNA) technology across three primary healthcare sectors: oncology, women's health, and organ health. Key products include Signatera (oncology), Panorama (prenatal), and Horizon (carrier screening). The company operates as a single reporting segment.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in millions) |
|---|---|
| Total Revenues | $1,449.4 |
| Net Loss | $(152.1) |
| Operating Loss | $(169.3) |
| Gross Margin | 64.6% |
| Cash and Cash Equivalents | $1,091.5 |
| Operating Cash Flow | $95.0 |
| Short-Term Debt (Credit Line) | $80.3 |
| Accumulated Deficit | $(2,928.1) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by 38.2% ($401.0 million) compared to the six months ended June 30, 2025. Product revenues grew 38.0%, driven by a 18.3% increase in reported test units and a 16.7% increase in Average Selling Price (ASP).
- Expense Increases:
- R&D Expenses: Increased 59.3% ($163.3 million) due to higher headcount, clinical trial investments, and new product development.
- SG&A Expenses: Increased 13.5% ($77.7 million), primarily due to higher compensation and marketing costs, partially offset by a $57.5 million decrease in legal and consulting expenses.
- Amortization: New amortization expense of $11.4 million related to intangible assets acquired from Foresight Diagnostics.
- Profitability: Net loss improved by 9.4% ($15.8 million) compared to the prior year period, despite higher operating expenses, largely due to significant revenue growth and favorable changes in revenue estimates.
- Acquisition Impact: The December 2025 acquisition of Foresight Diagnostics contributed to goodwill ($141.1 million) and intangible assets ($335.3 million), with contingent consideration liabilities totaling $120.5 million.
Guidance, Outlook, and Risks
- Liquidity: The company holds $1.1 billion in cash and has $20.0 million remaining on its $100 million credit line. Management believes existing cash is sufficient for at least 12 months.
- Revenue Estimates: The company recognized $113.3 million in additional revenue during the six months ended June 30, 2026, due to favorable changes in estimates regarding collections for tests delivered in prior periods. This reflects improved revenue cycle management and reimbursement rates.
- Legal Proceedings: Significant ongoing litigation includes:
- Guardant Health: A final judgment of $292.5 million for false advertising was entered in June 2026; Natera is appealing to the Ninth Circuit.
- ArcherDX/Invitae: Damages were reduced by ~$10 million, but an ongoing 30% royalty on post-judgment PCM product revenues was imposed. Appeals are pending.
- Ravgen: A $57.0 million judgment for patent infringement was entered in March 2026; Natera has filed an appeal.
- Risk Factors: Risks include reliance on third-party payers for reimbursement, the outcome of ongoing patent litigation, the ability to scale operations, and the need for additional financing to fund future R&D and commercialization.
Investor Verification Checklist
- Reimbursement Trends: Verify the sustainability of the 16.7% ASP increase and the $113.3 million revenue adjustment from prior period collections.
- Legal Exposure: Assess the potential financial impact of the $292.5 million Guardant judgment and the $57.0 million Ravgen judgment pending appeal.
- Contingent Consideration: Monitor the $120.5 million liability related to Foresight Diagnostics milestones and its potential dilution impact.
- Cash Burn vs. Growth: Evaluate the trajectory of R&D spending (up 59%) against revenue growth to determine the path to profitability.
- Debt Covenants: Review the terms of the UBS Credit Line, specifically the requirement to maintain $150 million in collateral.